AbbVie Inc.

The full register, from 13F filings

The Register tab above is hand research: a dozen holders, each traced to the filing it came from. This asks the same question of the whole market for the quarter ended 31-mar-2026, where 4,027 managers reported a position. Broad where the research is deep, and shallow in the ways a 13F always is.

Built from 13F filings, which report US listed, long, US custodied positions only. A register from this source is a floor rather than a level: a holder's true position can be far larger, as BlackRock's ASML stake shows at 1.28m shares in a 13F against 26.3m in its 13G/A. Holdings held through derivatives, outside US custody, or below a manager's reporting obligation do not appear. Where a holder is marked as a family, its total sums several separate filing entities and describes something no single filing describes; the constituent entities and their share counts are listed so the total can be checked. That roll-up can legitimately exceed the family's own Schedule 13G, because a 13G is filed by one legal entity: Vanguard reports Alphabet through ten advisory entities, and The Vanguard Group Inc itself reported zero after its January 2026 disaggregation.

What a reader needs to know to read these numbers

• AbbVie has no founder or dual class structure. It was spun off from Abbott Laboratories in 2013 as an independent public company with a single class of common stock, one vote per share, so there is no controlling family or founder voting block comparable to Eli Lilly's Lilly Endowment or Walmart's Walton family vehicles. The largest holders are all index or active asset managers.
• The eight institutional register rows are read from the pre-built 13F register at data/registers/ABBV.json (period 31 Mar 2026, source SEC Form 13F data set, filings Mar to May 2026) rather than re-derived. I spot checked two of the eight against the underlying filer level 13F information tables: BlackRock's own 13F-HR filed 13 May 2026 sums to 150,749,625 ABBV shares across 33 lines against the register's 150,698,125, a 0.03 percent difference likely from a later amendment or dedup step in how the register was built; Vanguard Capital Management LLC's 13F-HR matched exactly at 114,880,324 of its reported total. I did not re-verify the other six filer level sums given the time budget, and used the register's figures as filed.
• Percent of company for the institutional rows is computed, not filed: each holder's register share count divided by 1,766,792,821 shares of common stock outstanding as of 28 April 2026, the closest official share count to the 31 March 2026 13F measurement date, taken from the cover page of AbbVie's 10-Q for the quarter ended 31 March 2026.
• Vanguard and BlackRock also appear in AbbVie's 2026 proxy statement as the only two holders that crossed the 5 percent Schedule 13G disclosure threshold, but with different figures and dates than the 13F register: Vanguard 177,266,703 shares (10.02%) from a Schedule 13G/A filed 7 July 2025 reporting ownership as of 30 June 2025, and BlackRock, Inc. 143,180,060 shares (8.09%) from a Schedule 13G/A filed 25 January 2024 reporting ownership as of 31 December 2023. Both figures are lower than the 13F register's because a Schedule 13G is filed by one legal entity and reflects total beneficial ownership as of a single stale date, while the 13F register sums several affiliated advisory entities as of a more recent quarter. I used the 13F register figures above as the primary institutional rows per this task's instructions and record the 13G figures here rather than as separate rows, to avoid listing the same holder twice under two different measurement conventions.
• Insider overlap is marked per the known double counting bug: 'All directors and executive officers as a group (17 persons)' is the container (is_aggregate true), and the five named individuals below it each carry rolls_up_into pointing at that exact row. All 17 people in the table (13 non-employee directors, the CEO, and 4 other named executive officers) are members of this one group; AbbVie's proxy discloses no outside holder, such as a family trust or former officer, that sits apart from the group the way Walmart's Waltons or Microsoft's Ballmer and Gates do.
• The proxy states only that 'the directors and executive officers as a group own less than one percent of the outstanding shares of AbbVie' (footnote 4) and gives no precise percentage for the group or for any individual director or officer, so pct_of_company is left null on all six insider rows rather than invented. Using AbbVie's 10-Q cover count of 1,767,117,285 shares outstanding as of 27 July 2026 as an approximate denominator, the aggregate group's 1,020,964 shares would be about 0.058 percent; this is an approximation across mismatched dates (the ownership table is as of 6 March 2026), not a filed number.
• The Shares Beneficially Owned figures above exclude a separate 'Stock Options Exercisable within 60 days of March 6, 2026' column that the proxy reports alongside them (for example Robert A. Michael also holds 395,588 such options, and the group total for that column is 1,339,372). Only the beneficially owned share column is carried here to avoid mixing owned shares with unexercised options.
• AbbVie's own equity investments in other companies are small and undisclosed by counterparty. The 10-Q for the quarter ended 30 June 2026 reports investments in equity securities without readily determinable fair values carried at cost, with a carrying amount of $162 million as of 30 June 2026 (versus $159 million at 31 December 2025), remeasured only on observable price changes or impairment events; no individual investee names, share counts or values are given. The same 10-Q's fair value table separately shows $86 million of equity securities with readily determinable fair values ($48 million Level 1/2, the balance Level 2), which read as investment portfolio holdings (for example benefit plan or treasury related) rather than named strategic stakes. Neither bucket supports a named, sourced holdings row under this task's rules.